On Tuesday, Sage Therapeutics Inc (NASDAQ: SAGE) opened higher 0.18% from the last session, before settling in for the closing price of $5.56. Price fluctuations for SAGE have ranged from $4.62 to $28.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 3395.58% over the last five years. Company’s average yearly earnings per share was noted 28.02% at the time writing. With a float of $53.88 million, this company’s outstanding shares have now reached $61.17 million.
The firm has a total of 487 workers. Let’s measure their productivity. In terms of profitability, gross margin is 91.75%, operating margin of -349.3%, and the pretax margin is -317.29%.
Sage Therapeutics Inc (SAGE) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Sage Therapeutics Inc is 11.92%, while institutional ownership is 85.10%.
Sage Therapeutics Inc (SAGE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.80% during the next five years compared to -2.28% drop over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Check out the current performance indicators for Sage Therapeutics Inc (SAGE). In the past quarter, the stock posted a quick ratio of 10.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.58, a number that is poised to hit -1.53 in the next quarter and is forecasted to reach -3.86 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Analysing the last 5-days average volume posted by the [Sage Therapeutics Inc, SAGE], we can find that recorded value of 0.84 million was lower than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 47.98%. Additionally, its Average True Range was 0.37.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 10.73%, which indicates a significant decrease from 73.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.25% in the past 14 days, which was lower than the 80.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.30, while its 200-day Moving Average is $10.89. Now, the first resistance to watch is $5.70. This is followed by the second major resistance level at $5.83. The third major resistance level sits at $5.97. If the price goes on to break the first support level at $5.43, it is likely to go to the next support level at $5.29. Should the price break the second support level, the third support level stands at $5.16.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
There are currently 61,173K shares outstanding in the company with a market cap of 340.74 million. Presently, the company’s annual sales total 86,460 K according to its annual income of -541,490 K. Last quarter, the company’s sales amounted to 11,870 K and its income totaled -93,550 K.
